Creating a smoke-free generation The Lancet ++... ++...

Creating a smoke-free generation The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00854-8/fulltext?dgcid=raven_jbs_etoc_email May 02, 2026 Volume 407Number 10540p1657-1756 https://www.thelancet.com/journals/lancet/issue/vol407no10540/PIIS0140-6736(26)X2015-3 Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial Mette Kruse Klausen, MDa ∙ Signe Keller Justesen, MBa ∙ Julie Niemann Pedersen, RNa ∙ Line Rasmussen, MBa ∙ Andreas Jensen, PhDb ∙ Mathias Ebbesen Jensen, MDa ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00305-3/fulltext?dgcid=raven_jbs_etoc_feature_lancet Liver Health in Europe Following on from the first EASL-Lancet Commission, this second Commission highlights the structural determinants of liver disease and focuses on how to achieve improved and sustainable liver health in Europe. Mortality from liver cirrhosis remains persistently high and rates of liver cancer mortality have increased by more than 50% between 2000 and 2023. Primary prevention of liver cirrhosis and liver cancer by addressing risk factors such as obesity and alcohol use is not only benefitting liver health but many other non-communicable diseases. Such prevention efforts require a fundamental shift in thinking, moving away from the traditional, fragmented hepatology services toward integrated care models that embed liver disease prevention and management within broader health-care delivery that focuses on common risk factors. https://www.thelancet.com/commissions-do/europe-liver-health?dgcid=raven_jbs_etoc_feature_lanceteaslliver26